Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Medtronic
Baxter
Johnson and Johnson
Harvard Business School

Last Updated: January 16, 2022

DrugPatentWatch Database Preview

Details for Patent: 8,247,400


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,247,400 protect, and when does it expire?

Patent 8,247,400 protects TEFLARO and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 8,247,400
Title:Cephem compounds useful for the treatment of bacterial infections
Abstract: The present invention relates to new cephem compounds useful for the treatment of bacterial infections of formula I: ##STR00001## The invention also relates to methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and to methods of treatment using the compounds. The new cephem compounds are stable, exhibit good solubility, and are particularly well suited for, e.g., parenteral administration for the treatment of bacterial infections.
Inventor(s): Dedhiya; Mahendra G. (Pomona, NY), Singh; Brahma N. (Syosset, NY)
Assignee:
Application Number:12/710,417
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,247,400
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 8,247,400

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan TEFLARO ceftaroline fosamil POWDER;INTRAVENOUS 200327-001 Oct 29, 2010 AP RX Yes Yes ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial Y METHOD OF TREATING BACTERIAL INFECTIONS ⤷  Sign up for a Free Trial
Allergan TEFLARO ceftaroline fosamil POWDER;INTRAVENOUS 200327-002 Oct 29, 2010 AP RX Yes Yes ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial Y METHOD OF TREATING BACTERIAL INFECTIONS ⤷  Sign up for a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Colorcon
Harvard Business School
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.